← Leaderboards
Harrison Kim
Technology Commercialization Partners, Llc
$3,452,124
Attributed
$5,279,558
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,279,558 · 6
By mechanism
R01$3,212,321 · 2
UH3$980,071 · 1
UG3$763,402 · 1
R41$175,264 · 1
R03$148,500 · 1
Top collaborators
- Kyung Hyun Sung6 shared
- Bassel El-Rayes2 shared
- Ashiq Masood2 shared
Others in their field
Other Emerging Leaders on “Tissues”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$61,115,130
- Leonard Freedman · Leidos Biomedical Research, Inc.$54,559,980
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- Evan Z Macosko · Broad Institute, Inc.$33,867,067
Research focus
TissuesMeasurementPerfusionNamesTumorPortabilityMagnetic Resonance ImagingReproducibilityPoint Of CareContrast EnhancedImageRecruitAnatomyMoldsComputer SoftwareClinical Research SitePerformanceChemotherapyAlabamaRaceTechnologyNeoplasm MetastasisEffective TherapyContrast Media
Grant awards (15)
DCE-MRI guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer$657,895
R01 · FY2025 · CA · contact PI
Racially-associated MRI analysis and modeling for predicting aggressive prostate cancer$563,472
R01 · FY2025 · CA
Racially-associated MRI analysis and modeling for predicting aggressive prostate cancer$86,441
R01 · FY2025 · CA
DCE-MRI guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer$669,747
R01 · FY2024 · CA · contact PI
Racially-associated MRI analysis and modeling for predicting aggressive prostate cancer$532,300
R01 · FY2024 · CA
Racially-associated MRI analysis and modeling for predicting aggressive prostate cancer$82,119
R01 · FY2024 · CA
Diversity Supplements for Imaging Research in Prostate Cancer Health Disparities$42,567
R01 · FY2024 · CA
Racially-associated MRI analysis and modeling for predicting aggressive prostate cancer$577,780
R01 · FY2023 · CA
Disposable Perfusion Phantom for Accurate DCE-MRI Measurement of Pancreatic Cancer Therapy Response$479,816
UH3 · FY2022 · CA · contact PI
Accurate DCE-MRI Measurement of Glioblastoma using Point-of-care Portable Perfusion Phantom$74,250
R03 · FY2022 · CA · contact PI
Disposable Perfusion Phantom for Accurate DCE-MRI Measurement of Pancreatic Cancer Therapy Response$500,255
UH3 · FY2021 · CA · contact PI
Accurate DCE-MRI Measurement of Glioblastoma using Point-of-care Portable Perfusion Phantom$74,250
R03 · FY2021 · CA · contact PI
Disposable Perfusion Phantom for Accurate DCE-MRI Measurement of Pancreatic Cancer Therapy Response$367,205
UG3 · FY2020 · CA · contact PI
Disposable Perfusion Phantom for Accurate DCE-MRI Measurement of Pancreatic Cancer Therapy Response$396,197
UG3 · FY2019 · CA · contact PI
A Portable Device for Accurate Mouse Tail Vein Injection$175,264
R41 · FY2019 · OD · contact PI